Blueprint Medicines Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BIT:1BPMC Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
05 Mar 25	Sell€400,786	Becker Hewes	Individual	4,863	€82.42
05 Mar 25	Sell€290,926	Percy Carter	Individual	3,530	€82.42
05 Mar 25	Sell€109,283	Ariel Hurley	Individual	1,326	€82.42
05 Mar 25	Sell€307,656	Philina Lee	Individual	3,733	€82.42
05 Mar 25	Sell€425,016	Debra Durso-Bumpus	Individual	5,157	€82.42
05 Mar 25	Sell€534,793	Fouad Namouni	Individual	6,489	€82.42
05 Mar 25	Sell€1,331,089	Kathryn Haviland	Individual	16,151	€82.42
05 Mar 25	Sell€435,482	Michael Landsittel	Individual	5,284	€82.42
05 Mar 25	Sell€535,287	Christina Rossi	Individual	6,495	€82.42
05 Mar 25	Sell€433,669	Tracey McCain	Individual	5,262	€82.42
05 Mar 25	Sell€475,207	Jeffrey Albers	Individual	5,766	€82.42
03 Oct 24	Sell€294,613	Fouad Namouni	Individual	3,633	€81.09
05 Jun 24	Sell€387,005	Percy Carter	Individual	4,000	€96.75
03 Jun 24	Sell€190,743	Becker Hewes	Individual	1,951	€97.77
03 Jun 24	Sell€238,159	Percy Carter	Individual	2,436	€97.77

Insider Trading Volume

Insider Buying: 1BPMC insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of 1BPMC?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	679,879	0.953%
Hedge Funds	3,850,000	5.39%
Institutions	66,844,523	93.7%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 76.26% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
10.4%	T. Rowe Price Group, Inc.	6,718,647	€593.5m	5.37%	0.06%
10.4%	BlackRock, Inc.	6,710,696	€592.8m	-2.31%	0.01%
10.3%	The Vanguard Group, Inc.	6,640,523	€586.6m	-1.98%	0.01%
5.96%	Avoro Capital Advisors LLC	3,850,000	€340.1m	225%	6.23%
4.76%	Wellington Management Group LLP	3,073,306	€271.5m	-28.2%	0.05%
4.16%	State Street Global Advisors, Inc.	2,684,117	€237.1m	7.36%	0.01%
3.74%	JP Morgan Asset Management	2,418,174	€213.6m	133%	0.03%
2.36%	Geode Capital Management, LLC	1,522,647	€134.5m	2.18%	0.01%
2.22%	FMR LLC	1,432,289	€126.5m	-36.2%	0.01%
2.21%	William Blair Investment Management, LLC	1,429,668	€126.3m	-26.5%	0.18%
1.99%	Macquarie Investment Management Business Trust	1,286,897	€113.7m	2.22%	0.17%
1.85%	AllianceBernstein L.P.	1,196,240	€105.7m	5.12%	0.04%
1.56%	Rock Springs Capital Management LP	1,007,569	€89.0m	-8.14%	5.85%
1.48%	Pictet Asset Management Limited	954,596	€84.3m	-19.4%	0.06%
1.39%	Hood River Capital Management LLC	900,205	€79.5m	2.3%	1.46%
1.38%	Invesco Ltd.	890,564	€78.7m	2.02%	0.02%
1.34%	American Century Investment Management Inc	866,763	€76.6m	3.28%	0.04%
1.34%	Eventide Asset Management, LLC	862,549	€76.2m	0.03%	1.59%
1.16%	Alkeon Capital Management, LLC	751,368	€66.4m	12.7%	0.47%
1.12%	Artal Group S.A.	726,167	€64.1m	0%	2.68%
1.1%	Norges Bank Investment Management	711,164	€62.8m	0%	0.01%
1.07%	Millennium Management LLC	691,395	€61.1m	-6.23%	0.06%
1.04%	ClearBridge Investments, LLC	671,617	€59.3m	36.9%	0.05%
1.01%	Emerald Advisers, LLC	651,802	€57.6m	-4.96%	1.68%
0.93%	Charles Schwab Investment Management, Inc.	599,721	€53.0m	-0.77%	0.01%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/23 20:24
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Blueprint Medicines Corporation is covered by 36 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Colleen Kusy	Baird
Ishan Majumdar	Baptista Research
Peter Lawson	Barclays